Shanghai Enjosim Medical Technology Co., Ltd is located in Zhoupu International Medical Park, Pudong, Shanghai. Since 2018, the company has been relying on its wholly-owned subsidiary, Changshu Kangxin Medical Instrument Co, Ltd focuses on the R&D, production, and sales of self delivery systems, especially for biological macromolecular drugs.
The company's technical team has been engaged in the R&D of self medication systems for over 10 years, and the technical leader of the team is one of the experts in formulating industry standards for high-precision pen injector in China. At present, the company is selling multiple high-precision pen injector that are compatible with biological agents such as insulin, growth hormone, Smeglutide, and GLP-1. The company's research products include intelligent subcutaneous injection pens, application type drug delivery devices, inhalation type drug delivery devices, and microneedle injection devices. Currently, the company has applied for 16 product patents.
Year of Establishment:
2021
Total Assets(USD):
Total Number of Staff:
Main Competitive Advantages:
Other Competitive Advantages:
Patents and Copyrights:
Business Type:
Trading Company,Service Provider,Manufacturer
R&D capacity:
OEM,ODM,Own Brand
Annual Turnover(USD):
500,000 to 99,999,999
Main Sales Markets:
North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Africa
Other Competitive Advantages:
Patents and Copyrights:
Audited Supplier
Pharma Sources Insight June 2024: Globalization on the Go
